Featured Story | By Annalee Armstrong For a long time, gene and cell therapies were a treatment option for the future. Now, the pace of development is moving at breakneck speed, with a number of firsts and $14.1 billion in financing collected over the initial half of the year. The Alliance for Regenerative Medicine has documented the “acceleration on all fronts” in a new report looking at the first half of 2021. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Vigil Neuroscience is barreling forward with a strategy that will see it hop along steppingstones from rare diseases to Alzheimer’s. Having emerged with $50 million late last year, Vigil has gathered up an additional $90 million to validate its ex-Amgen asset in a rare, inherited neurodegenerative disease. read more By Amirah Al Idrus Marinus Pharmaceuticals is gearing up for a phase 3 study after its epilepsy drug curbed seizures in patients with a rare, genetic disease that causes benign tumors to grow in various parts of the body, including the brain. The treatment, ganaxolone, reduced the seizure frequency over four weeks of patients with tuberous sclerosis complex by 16.6%. read more Sponsored By: BioIVT Machine-learning-based techniques in drug and diagnostic discovery require copious amounts of biomedical data, and that data needs to be validated to ensure success. read more By Amirah Al Idrus After years chasing a hard-to-drug group of targets called solute carriers, Jnana Therapeutics is revealing its lead program and a new $50 million financing to get it into the clinic. That program targets phenylketonuria, a rare, inherited disorder in which the amino acid phenylalanine builds up in the blood and brain. read more By Kyle LaHucik Immunitas is attempting to tackle the hurdles traditionally associated with checkpoint inhibitors, which don't work for everyone and typically require combination regimens with investigational drugs to boost their clinical potential. The biotech is now one step closer to moving its programs into the clinic. read more By Nick Paul Taylor Add another biotech to the list of protein degrader startups. Weeks after Pfizer’s landmark deal with Arvinas, Sino-American biotech Ranok Therapeutics has unveiled a $40 million series B round to fund work on a cancer program. read more By Kyle LaHucik Exscientia has already found a drug candidate in its $1.2 billion partnership with Bristol Myers Squibb. The Big Pharma will pay the AI-powered drug miner $20 million for the option fee just three months after expanding their collaboration, which included a $50 million upfront payment. read more By Andrea Park Making good on its pledge to expand the reach of Project Baseline, its clinical research platform, Verily is set to acquire SignalPath, developer of an eponymous platform that, like Baseline, aims to make the entire clinical trial process more efficient. read more By Angus Liu GlaxoSmithKline’s PD-1 latecomer Jemperli has scored an FDA go-ahead to expand into a larger cancer field. Once again, it’s following in the footsteps of Merck’s market leader Keytruda, but first-in-class opportunities await down the line. read more By Heather Landi The Biden administration is investing $19 million to expand telehealth in rural and underserved communities to help increase access to care during the COVID-19 pandemic. Among other things, the investments will provide funding for telehealth incubators to pilot new telehealth services and track outcomes in rural medically underserved areas that have high chronic disease prevalence and high poverty rates. read more Resources Sponsored by: XIFIN inc. Download Frost & Sullivan’s enabling technologies best practices report to learn more about the four core functionalities required in successful precision medicine programs. Sponsored by: Patheon by Thermo Fisher Scientific Learn how a decentralized clinical trial strategy improves patient recruitment, reduces drop-out rates, and ultimately streamlines the path to the next trial phase. Sponsored by: Patheon by Thermo Fisher Scientific Learn how to build a robust packaging strategy and the key technical considerations in packaging design and operational planning to enable rapid commercialization of pharmaceuticals. Sponsored by: Patheon by Thermo Fisher Scientific Learn how regulations are changing and key considerations for commercializing cell and gene therapies without sacrificing quality. Sponsored By: LabVantage Solutions, Inc. Uncover the real impact of “digital transformation” with practical advice to help you plan your own transformative journey to a harmonized digital ecosystem. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. | 
